ESR1 and cancer: Estrogen receptor (ER) and progesterone receptor (PR) status was identified as 67% (ER +) and 50% (PR +) with 22% unidentified in excised pre-cancer tissue of the control group, whereas the treated patient’s tissues were 89% (ER +) and 81% (PR +) with 11% unidentified.